A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01
Latest Information Update: 21 Feb 2022
At a glance
- Drugs RH 5.1 (Primary) ; AS01B
- Indications Falciparum malaria
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Jul 2021 New trial record
- 21 Apr 2021 According to an ExpreS2ion Biotechnologies Media Release, the study was funded by Leidos Inc. as part of the company's prime contract with the United States Agency for International Development (USAID) for the creation and testing of malaria vaccines.